Abstract 101P
Background
Deep molecular analysis with high throughput technology has improved the outcomes of advanced cancer patients. The molecular tumor board has a fundamental role in guiding treatment offering the evaluation of those molecular variants beside the ESCAT 1 level of evidence.
Methods
2010 patients diagnosed with solid tumors were prospectively analyzed in our institution with an extensive NGS panel. Patients were molecularly selected to receive a molecular-matched treatment according to international guidelines or to be enrolled in early phase trials, based on the evaluation of a single institution multidisciplinary molecular tumor board.
Results
1726 of 2010 (85.9%) patients presented any genomic or transcriptomic alterations. Of those, 1086 (62.9%) presented with advanced disease. 128 patients (11.8%) received standard targeted agents. 161 (14.8%) patients presented with druggable mutations beyond ESCAT 1 level such as BRAFnoV600, FGFR, NRAS, PIK3CA, ERBB2 and DNA repair genes, and BRAF fusions. Finally, 67 (6.1%) of those patients entered an early-phase clinical trial to receive a novel molecular-matched approach.
Conclusions
We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of an extensive NGS panel. This process optimizes the selection of experimental novel molecular-matched therapies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
82P - Applying computational approaches to build a predictive protein structure and discover novel inhibitors for mitotic serine/threonine kinase BUB1B
Presenter: Joan Glenny Pescov
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Development of a cell-free DNA scoring system from organoid culture medium to predict drug response in bladder cancer
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Quinacrine inhibits angiogenesis and migration of non-small cells lung cancer cells (NSCLC) by binding with the kinase domain of VEGFR2
Presenter: Angshuman Sarkar
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - HDAC6-mediated regulation of progesterone receptor: Implications for hormonal therapy in breast cancer
Presenter: Wafaa Ramadan
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Functional impact of miR-205-5p on cervical cancer cell behavior and chemotherapy response
Presenter: Rhafaela Causin
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Impact of poly(ADP-ribose) polymerase (PARP) mutations on interaction with PARP inhibitors (iPARPs)
Presenter: JUAN DIAZ ACOSTA
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Epstein-Barr virus-positive and Epstein-Barr virus-negative nasopharyngeal carcinoma in multicellular spheroid model
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Clinical phenotyping of lung cancer-associated cachexia in relation to tumour volume in TRACERx
Presenter: Kexin Koh
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - Are patients with measurable residual disease (MRD) positive or MRD negative different in baseline DNA methylation signatures in precursor B-cell acute lymphoblastic leukaemia (B-ALL)?
Presenter: Ramya Ramesh
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Prognostic value of tumor location and site-specific metastases in advanced biliary tract cancer
Presenter: Vanessa Patel
Session: Cocktail & Poster Display session
Resources:
Abstract